Although relatively large, the BEAT-ROP study was not adequately powered to determine the safety of anti-VEGF in the developing child and some concerns remain regarding the potentially unknown long-term local and systemic side effects of these medications. The gene discussed is VEGFA; the disease is retinopathy of prematurity.